Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis

BACKGROUND: Mechanisms of resistance have been described during disease progression (PD) for patients under treatment with anti-EGFR plus chemotherapy (CT). The aim of our study was to evaluate efficacy of anti-EGFR rechallenge (ReCH) and reintroduction (ReIn) in metastatic colorectal cancer (mCRC)....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ecancermedicalscience
Hlavní autoři: Karani, Amanda, Felismino, Tiago Cordeiro, Diniz, Lara, Macedo, Mariana Petaccia, Silva, Virgilio Souza e, Mello, Celso Abdon
Médium: Artigo
Jazyk:Inglês
Vydáno: Cancer Intelligence 2020
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7373642/
https://ncbi.nlm.nih.gov/pubmed/32728385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2020.1069
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky